# Cingulate (stock symbol: CING) Logo in transparent PNG format

## Cingulate Logo large

### Cingulate Logo large Download PNG (3.95 KB)

![Cingulate Logo large Download PNG (3.95 KB)](/img/orig/CING_BIG-a669a709.png)

## Cingulate Logo icon format

### Cingulate Logo icon format Download PNG (1.27 KB)

![Cingulate Logo icon format Download PNG (1.27 KB)](/img/orig/CING-7a8013b4.png)

## About Cingulate

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

1. Website domain: cingulate.com
2. Employees: 16
3. Marketcap: $12.61 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
